Tiragolumab

Tiragolumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting TIGIT/VSIG9/VSTM3, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Tiragolumab is a humanized monoclonal antibody. Tiragolumab targets TIGIT and directly or indirectly activates the anti-tumor immune response by acting on the activation pathways of APC and T cells and NK cells to achieve the purpose of eliminating tumor cells.

Target	TIGIT/VSIG9/VSTM3
Clonality	Monoclonal
Reactivity	Human
Expression	Recombinant
Tested Applications	ELISA, WB
Host	Human
Recommended dilutions	Optimal dilutions/concentrations should be determined by the end user.
Conjugation	Unconjugated
Isotype	IgG1 Kappa
Form	Liquid
Purity	> 95%
Purification	Purified from cell culture supernatants by Protein A/G chromatography.
Storage	Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Buffer	0.01 M PBS. pH 7.4.
CAS Number	1918185-84-8
Concentration	Batch-dependent, typically between 0.5-2.0 mg/ml.
Availability	Shipped within 7-12 working days.
Note	This product is for research use only. Not for human consumption, cosmetic, therapeutic or diagnostic use.

Research Articles on TIGIT/VSIG9/VSTM3

Write a review

Your Name

Your Email Address

PMID

DOI

Your Review

Rating

Continue